Dapiprazole
From Wikipedia, the free encyclopedia
Not to be confused with Aripiprazole.
 |
|
|
Dapiprazole
|
|
| Systematic (IUPAC) name | |
| 3-{2-[4-(2-methylphenyl)piperazin-1-yl]ethyl}-5,6,7,8- tetrahydro-[1,2,4]triazolo[4,5-a]pyridine |
|
| Identifiers | |
| CAS number | |
| ATC code | S01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C19H27N5 |
| Mol. mass | 325.451 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | Negligible when administered topically |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
B(US) |
| Legal status | |
| Routes | Topical (eye drops) |
Dapiprazole (U.S. trade name Rev-Eyes) is an alpha blocker. It is used to reverse mydriasis after eye examination.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
||||||||||||||||||||
